Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. NewAmsterdam Pharma Company NV shares valued at $1,076,290 were sold by ForGrowth NAP B.V. on Dec 27 ’24. At $25.95 per share, ForGrowth NAP B.V. sold 41,472 shares. The insider’s holdings dropped to 10,686,018 shares worth approximately $274.63 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ForGrowth NAP B.V. sold 33,438 shares, netting a total of over 869,629 in proceeds. Following the sale of shares at $26.01 each, the insider now holds 10,727,490 shares.
Before that, ForGrowth NAP B.V. had sold 49,772 shares from its account. In a trade valued at $1,274,064, the 10% Owner traded NewAmsterdam Pharma Company NV shares for $25.60 each. Upon closing the transaction, the insider’s holdings decreased to 49,772 shares, worth approximately $277.62 million.
As published in their initiating research note from H.C. Wainwright on December 30, 2024, NewAmsterdam Pharma Company NV [NAMS] has been a Buy and the price target has been revised to $48. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid May. As of March 14, 2024, Scotiabank has initiated its “Sector outperform” rating for NAMS. Earlier on January 18, 2024, Guggenheim initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
During the last five days, there has been a surge of approximately 0.27%. Over the course of the year, NewAmsterdam Pharma Company NV shares have jumped approximately 130.08%. Shares of the company reached a 52-week high of $27.29 on 12/11/24 and a 52-week low of $11.18 on 01/02/24. A 50-day SMA is recorded $22.09, while a 200-day SMA reached $19.67. Nevertheless, trading volume fell to 0.89 million shares from 0.46 million shares the previous day.
Support And Resistance Levels for NewAmsterdam Pharma Company NV (NAMS)
According to the 24-hour chart, there is a support level at 25.39, which, if violated, would cause prices to drop to 25.09. In the upper region, resistance lies at 26.09. The next price resistance is at 26.49. RSI (Relative Strength Index) is 61.13 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.11, which suggests the price will decrease in the coming days. Percent R is at 54.64%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
